CRISPR/Cas9

Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's co-developing with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), produced positive...

2016’s slow start for Initial Public Offerings (IPO) could be over, as four biotechs follow in the wake of several successful IPOs, most notably, BATS Global Markets, Inc. (BATS: BATS) and American Renal Associates Holdings Inc (NYSE: ARA). These stocks are up 25 and 26 percent, respectively...